FDA Expands Jardiance Approvals to Include Heart Failure Patients With Preserved Ejection Fraction

By PacConAdmin | February 25, 2022

Jardiance (empagliflozin), the type 2 diabetes and cardiovascular blockbuster developed by Eli Lilly and Boehringer Ingelheim, has expanded its indications with a new approval for reducing the risk of cardiovascular death and hospitalization in adults with heart failure and preserved left ventricular ejection fraction (LEVF).
Source: Drug Industry Daily

Posted in Drug Industry Daily